Erika Morsia

Ancona, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 57 publications

Comment on 'Context, not class, may be the key signal in systemic Janus kinase inhibitor exposure in mycosis fungoides/Sézary syndrome': reply from authors.

Comment on 'Context, not class, may be the key signal in systemic Janus kinase inhibitor exposure in mycosis fungoides/Sézary syndrome': reply from authors.

Journal: The British journal of dermatology

Published: June 03, 2026

A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib.

A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib.

Journal: Blood advances

Published: February 27, 2026

A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib.

A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib.

Journal: Blood advances

Published: February 27, 2026

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study.

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study.

Journal: Cancer

Published: February 19, 2026

Characteristics and Outcomes of Progressive Multifocal Leukoencephalopathy in Hematologic Malignancies: A SEIFEM Retrospective Review.

Characteristics and Outcomes of Progressive Multifocal Leukoencephalopathy in Hematologic Malignancies: A SEIFEM Retrospective Review.

Journal: American journal of hematology

Published: February 09, 2026

An Italian cartography of VEXAS-related thrombosis.

An Italian cartography of VEXAS-related thrombosis.

Journal: HemaSphere

Published: January 17, 2026

Mycosis fungoides/Sézary syndrome and systemic Janus kinase inhibitors: a real-world retrospective study on behalf of the EORTC CLTG.

Mycosis fungoides/Sézary syndrome and systemic Janus kinase inhibitors: a real-world retrospective study on behalf of the EORTC CLTG.

Journal: The British journal of dermatology

Published: December 21, 2025

Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis.

Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis.

Journal: Cancer

Published: December 16, 2025

Patient and care partner burden in cutaneous T-cell lymphoma using disease-specific measures of symptoms and health-related quality of life.

Patient and care partner burden in cutaneous T-cell lymphoma using disease-specific measures of symptoms and health-related quality of life.

Journal: The British journal of dermatology

Published: November 26, 2025

Overall survival with momelotinib vs. best available therapy in patients with ruxolitinib-experienced myelofibrosis: a matching-adjusted indirect comparison.

Overall survival with momelotinib vs. best available therapy in patients with ruxolitinib-experienced myelofibrosis: a matching-adjusted indirect comparison.

Journal: Annals of hematology

Published: November 14, 2025

Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).

Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).

Journal: Hematological oncology

Published: November 13, 2025

The Strange Case of Functional High-Risk Multiple Myeloma Patients: Is It Possible to Identify Them in Clinical Practice?

The Strange Case of Functional High-Risk Multiple Myeloma Patients: Is It Possible to Identify Them in Clinical Practice?

Journal: Cancers

Published: October 08, 2025

Showing 1-12 of 57

Last Updated: 09/26/2026